INHIBITION OF T CELLS BY A TUMOR ASSOCIATED PROTEIN
INHIBITION OF T CELLS BY A TUMOR ASSOCIATED PROTEIN
批准号:
6258523
负责人:
STEPHEN L. ECK
金额:
$24.04万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-05-01 至 2006-04-30
中文摘要
描述:(改编自申请人摘要)肿瘤逃避免疫
英文摘要
DESCRIPTION: (Adapted from applicant's abstract) Tumors evade immune
surveillance despite the frequent expression of tumor-associated antigens that
can be recognized by T cells. While a number of mechanisms have been described
to explain tumor cell escape from recognition by CD8+ T cells, few studies have
addressed tumor cell evasion of CD4+ T cell responses; nevertheless, optimal
anti-tumor immune responses require the participation of both CD8+ and CD4+ T
cells specific for tumor-associated antigens. Here, we show that mouse
epithelial glycoprotein (mEGP), the mouse homologue of a human carcinoma
associated antigen GA733-2, blocks antigen-specific MHC class II T cell
activation induced by bone marrow derived dendritic cells. mEGP also blocks
activation of transgenic T cells in the presence of their cognate peptide and
protein antigens (e.g., hen egg lysozyme and ovalbumin). We hypothesize that
the blockade occurs at the level of antigen presentation by the dendritic
cells, and occurs by interfering with the assembly of MIHC class Il peptide
complex. These results mirror the down-regulation of MIHC class I-associated
antigen presentation in many tumors, and demonstrate a novel mechanism by which
a tumor-associated antigen participates in subverting an anti-tumor immune
response. In this application we will first establish that mEGP functions
solely at the level of the antigen presenting cell and has no direct effect on
the T cell (Aim 1). Then we will determine which portions of the mEGP protein
are needed for its inhibitory effect and whether this effect occurs at the
level of the endosome (Aim 2). Finally, we will determine whether the human
protein GA733 has similar activity in a human T cell system (Aim 3). The human
model will be used to explore whether the effects of mEGP and GA733 are due to
alteration of cathepsin activity which is known to play a role in class II
assembly (Aim 3). The overall objective is to identify the molecular pathway by
which these proteins function and in doing so provide a framework for
understanding their biologic functions in normal and neoplastic cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MECHANISMS OF ADENOVIRUS VACCINES FOR COLON CANCER
-
批准号:6563875
-
项目类别:
-
资助金额:$22.84万
-
财政年份:2002
-
负责人:STEPHEN L. ECK
-
依托单位:
MECHANISMS OF ADENOVIRUS VACCINES FOR COLON CANCER
-
批准号:6410215
-
项目类别:
-
资助金额:$22.84万
-
财政年份:2001
-
负责人:STEPHEN L. ECK
-
依托单位:
TREATMENT OF RECURRENT/PROGRESSIVE MALIGNANT GLIOMA WITH H5 010CMVHINF ADENOVIRUS
-
批准号:6565876
-
项目类别:
-
资助金额:$12.41万
-
财政年份:2001
-
负责人:STEPHEN L. ECK
-
依托单位:
TREATMENT OF RECURRENT/PROGRESSIVE MALIGNANT GLIOMA WITH H5 010CMVHINF ADENOVIRUS
-
批准号:6468126
-
项目类别:
-
资助金额:$12.41万
-
财政年份:2000
-
负责人:STEPHEN L. ECK
-
依托单位:
MECHANISMS OF ADENOVIRUS VACCINES FOR COLON CANCER
-
批准号:6300546
-
项目类别:
-
资助金额:$15.41万
-
财政年份:2000
-
负责人:STEPHEN L. ECK
-
依托单位:
MECHANISMS OF ADENOVIRUS VACCINES FOR COLON CANCER
-
批准号:6103374
-
项目类别:
-
资助金额:$15.41万
-
财政年份:1999
-
负责人:STEPHEN L. ECK
-
依托单位:
MECHANISMS OF ADENOVIRUS VACCINES FOR COLON CANCER
-
批准号:6269841
-
项目类别:
-
资助金额:$16.92万
-
财政年份:1998
-
负责人:STEPHEN L. ECK
-
依托单位:
DEVELOPMENT, CHARACTERIZATION, AND PRODUCTION OF A B7 ADENOVIRUS VECTOR
-
批准号:6103017
-
项目类别:
-
资助金额:$14.97万
-
财政年份:1997
-
负责人:STEPHEN L. ECK
-
依托单位:
RECOMBINANT ADENOVIRUS VACCINE FOR COLON CANCER
-
批准号:2458280
-
项目类别:
-
资助金额:$16.15万
-
财政年份:1996
-
负责人:STEPHEN L. ECK
-
依托单位:
RECOMBINANT ADENOVIRUS VACCINE FOR COLON CANCER
-
批准号:2010235
-
项目类别:
-
资助金额:$19.71万
-
财政年份:1996
-
负责人:STEPHEN L. ECK
-
依托单位:
DEVELOPMENT, CHARACTERIZATION, AND PRODUCTION OF A B7 ADENOVIRUS VECTOR
-
批准号:6237508
-
项目类别:
-
资助金额:$14.39万
-
财政年份:1996
-
负责人:STEPHEN L. ECK
-
依托单位:
海外基金